Antibiotic Prophylaxis for Surgical Site Infection in General Surgery: Oncological Treatments and HIPEC

Carlo Vallicelli, Federico Coccolini, Massimo Sartelli, Luca Ansaloni, Simona Bui, Fausto Catena

Research output: Contribution to journalArticlepeer-review


The procedure of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a combined surgical and oncological treatment for peritoneal carcinomatosis of various origins. Antibiotic prophylaxis is usually center-related and should be discussed together with the infectious disease specialist, taking into account the advanced oncologic condition of the pa-tient, the complexity of surgery—often requiring multiorgan resections—and the risk of post-HIPEC neutropenia. The incidence of surgical site infection (SSI) after CRS and HIPEC ranges between 11 and 46%. These patients are also at high risk of postoperative abdominal infections and septic complications, and a bacterial translocation during HIPEC has been hypothesized. Many authors have proposed aggressive screening protocols and a high intra and postoperative alert, in order to minimize and promptly identify all possible infectious complications following CRS and HIPEC.

Original languageEnglish
Article number43
Issue number1
Publication statusPublished - Jan 2022


  • Antibiotic prophylaxis
  • Surgical oncology
  • Surgical site infection

ASJC Scopus subject areas

  • Microbiology
  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Antibiotic Prophylaxis for Surgical Site Infection in General Surgery: Oncological Treatments and HIPEC'. Together they form a unique fingerprint.

Cite this